Racecadotril in the Treatment of Acute Diarrhoea in Adults. An Individual Patient Data Based Meta-Analysis


Racecadotril is an antidiarrhoeal drug with a pure intestinal antisecretory mechanism of action. Aim: To assess racecadotril efficacy, whatever its dose, versus placebo in adult acute diarrhoea. Methods: Individual Patient Data meta-analysis following multilevel mixed models testing of the significance of the treatment effect adjusted for baseline covariates. Diarrhoea duration was the common main criteria. Results: Four randomized clinical trials (n = 669) were identified with raw data. The clinical global impression evaluated at baseline by the physician was found to be the essential predictor influencing the outcome. As compared to placebo, the 100 mg dose, the minimum effective dose, induced a 80% increase of the recovered patient proportion at anytime (Hazard Ratio = 1.8 [1.3, 2.5], p < 0.001), a 60% increase of the responder proportion i.e. recovery within 3 days (p < 0.001), a 47% reduction of abdominal pain and nausea and an overall 33% decrease of sick days (p < 0.001). In conclusion, as compared to placebo, racecadotril induced several significant effects, such as reducing the diarrhoea duration, the number of stools and associated symptoms, leading to less lost productivity.

Share and Cite:

Coffin, B. , Hamza, H. , Vetel, J. and Lehert, P. (2014) Racecadotril in the Treatment of Acute Diarrhoea in Adults. An Individual Patient Data Based Meta-Analysis. International Journal of Clinical Medicine, 5, 345-360. doi: 10.4236/ijcm.2014.57051.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Garthright, W.E., Archer, D.L. and Kvenberg, J.E. (1988) Estimates of Incidence and Costs of Intestinal Infections Diseases in the United States. Public Health Reports, 103, 107-115.
[2] Baldi, F., Bianco, M.A., Nardone, G., Pilotto, A. and Zamparo, E. (2009) Focus on Acute Diarrhoeal Disease. World Journal of Gastroenterology, 15, 3341-3348. http://dx.doi.org/10.3748/wjg.15.3341
[3] Eberlin, M., Mück, T. and Michel, M.C. (2012) Comprehensive Review of the Pharmacodynamics, Pharmacokinetics and Clinical Effects of the Neutral Endopeptidase Inhibitor Racecadotril. Frontiers in Pharmacology, 93, 1-16.
[4] Vetel, J.M., Hamza, H., Coffin, B. and Lehert, P. (2014) Racecadotril Efficacy in the Symptomatic Treatment of Adult Acute Diarrhoea. A Systematic Review and Meta-Analysis. International Journal of Clinical Medicine, in press.
[5] Baumer, P., Danquechin-Dorval, E., Bertrand, J., Vetel, J.M., Schwartz, J.C. and Lecomte, J.M. (1992) Effects of Acetorphan, an Enkephalinase Inhibitor, on Experimental and Acute Diarrhoea. Gut, 33, 753-758.
[6] Hamza, H., Ben Khalifa, H., Baumer, P., Berard H. and Lecomte, J.M. (1999) Racecadotril versus Placebo in the Treatment of Acute Diarrhoea in Adults. Alimentary Pharmacology & Therapeutics, 13, 15-19.
[7] Moraes, E., Chinzon, D., Coelho, L.G., Fernandes, T.F., Haddad, M.T. and the Brazilian Racecadotril Investigators Research Group (2001) A Multicentric, Randomised, Investigator-Blind, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Racecadotril versus Saccharomyces boulardii in the Treatment of Acute Diarrhoea in Adults. [Estudo Multicentrico de Grupos Paralelos, Randomizado, Cego para o Investigator, para Avaliar a Eficacia, Seguranca e Tolerabilidade do Racecadotril versus Saccharomyces boulardii no tratamento da diarreia aguda em adultos]. Revista Brasileira de Medicina, 56, 65-74.
[8] Duncan, A.J. (1986) Quality Control and Industrial Statistics. 5th Edition, Irwin, Homewood.
[9] Core Team, R. (2013) A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna. http://www.R-project.org/
[10] Higgins, J.P., Whitehead, A., Turner, R.M., Omar, R.Z. and Thompson, S.G. (2001) Meta-Analysis of Continuous Out-come Data from Individual Patients. Statistics in Medicine, 20, 2219-2241. http://dx.doi.org/10.1002/sim.918
[11] Tudur-Smith, C. and Williamson, P.R. (2007) A Comparison of Methods for Fixed Effects Meta-Analysis of Individual Patient Data with Time to Event Outcomes. Clinical Trials, 4, 621-630. http://dx.doi.org/10.1177/1740774507085276
[12] Edwards, D. (1999) On Model Prespecification in Confirmatory Randomized Studies. Statistics in Medicine, 18, 771-785. http://dx.doi.org/10.1002/(SICI)1097-0258(19990415)18:7<771::AID-SIM80>3.0.CO;2-E
[13] Durand, C.P. (2013) Does Raising Type 1 Error Rate Improve Power to Detect Interactions in Linear Regression Models? A Simulation Study. PLoS ONE, 8, e71079. http://dx.doi.org/10.1371/journal.pone.0071079
[14] DerSimonian, R. and Laird, N. (1986) Meta-Analysis in Clinical Trials. Controlled Clinical Trials, 7, 177-188.
[15] ICH E9 (1998) Statistical Principles for Clinical Trials.
[16] Good Clinical Practice (1987) Les Bonnes Pratiques Cliniques. Bulletin Officiel no. 87-32bis.
[17] WHO (1987) Guidelines for Planning Clinical Trials in Diarrhoeal Diseases. WHO/CDD/CMT/87.2.
[18] FDA (1977) Guidelines for the Clinical Evaluation of Antidiarrheal Drugs, HEW (FDA) 78-3049.
[19] Khediri, F., Mrad, A.I., Azzouz, M., Doughi, H., Najjar, T., Mathiex-Fortunet, H., Garnier, P. and Cortot, A. (2011) Efficacy of Diosmectite (Smecta®) in the Treatment of Acute Watery Diarrhoea in Adults: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study. Gastroenterology Research and Practice, 2011, Article ID: 783196. http://dx.doi.org/10.1155/2011/783196

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.